Main Library
CMMI releases three new models aimed at lower generic, novel drug costs

CMMI releases three new models aimed at lower generic, novel drug costs

February 14, 2023Robert KingFierce HealthcareMedicare, MA, MSSP, & Medicare ACOs,Pharmacy Services,CMS, CMMI, Government, Policy & Regulations

The Biden administration rolled out three new payment models intended to lower drug costs, including new Medicare coverage options for drugs cleared under accelerated approval.

The release of the three models on Tuesday is in response to an executive order President Biden delivered last year calling for the federal government to search for ways to lower prices.

“These selected models will test strategies to make it easier for Medicare patients to afford and access needed prescriptions at $2 or less, help expand access to cutting-edge cell and gene therapies for people with Medicaid, and help ensure drugs already on the market are safe and effective,” said Center for Medicare and Medicaid Innovation Director Liz Fowler in a statement.

Full Article

: ACO care teams, ACO participation, CMMI, CMMS, group practice, MSSP, SDOA, SDOH, SDOHY

Related Posts

New coalition calls for collective action on health equity

December 20, 2022aco

Incorporating social determinants of health: Simplest solution may give the best results

October 7, 2021Garrett Schmitt

Digital health companies must act on health equity. This is the time.

August 3, 2022aco

Recent Posts

  • The ‘price’ of value-based care
  • The Evolving Physician Advisor: From UM to Value-Based Care & AI
  • CMMI Announces Make America Healthy Again Strategy, Prioritizes Choice For Care Settings, Including In Homes
  • RECORDED WEBINAR: Best Value-Based Care Strategies PT 2: Controlling Specialty Patient Care Costs and Total Costs for Negotiating Leverage
  • A More Holistic Approach To Measurement For Value-Based Care
 
  • Main Lobby
  • Exhibit Hall
  • Events
  • Exhibit With Us
  • Board Room
  • Library
  • Contact Us